English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Ramosetron is a new selective 5-hydroxytryptamine type 3 (5HT3) receptor antagonist that reportedly has more potent antiemetic effects compared with other 5HT3 receptor antagonists. The purpose of this study was to evaluate the efficacy of Ramosetron for the prevention of postoperative nausea and vomiting (PONV) with that of Ondansetron in patients undergoing gynecological surgery. Materials and Methods: In this prospective study, 50 healthy patients who were undergoing gynecological operation under general anaesthesia using sevoflurane were enrolled. Patients were divided into two groups: the Ramosetron group (0.3 mg i.v.; n=25) and the Ondansetron group (8 mg i.v.; n=25). The treatments were given 30 minutes before the end of surgery. The incidence of PONV, severity of nausea, and the use of rescue antiemetic requirements during the first 24 h after surgery were evaluated as two groups (0-6 hours and 6-24 hours). Results: The incidence of nausea in the first 6 hours after the surgery in the Ramosetron and Ondansetron groups was 4% & 20% respectively, which was statistically insignificant where as late nausea (6-24 hrs) was 12% and 40% which was statistically significant. 2 patients in the Ondansetron group and none in the Ramosetron group had vomiting during the first 6 hours, which was statistically insignificant, whereas none in the Ramosetron group and 32% of patients in Ondansetron group had vomiting during the late postoperative period of 6-24 hours which was statistically significant. Conclusions: So it was concluded that Ramosetron 0.3 mg i.v. was as effective as Ondansetron 8 mg i.v. in decreasing the incidence of PONV and reducing nausea severity in female patients during the first 6 h after gynecological surgery but Ramosetron was found to be more effective than Ondansetron in prevention of PONV in the 6-24 hours period after the surgery.

Comparison of Ramosetron with Ondansetron for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Gynecological Surgery